A Study on the Bioequivalence of Bupivacaine Liposome Injection in Humans

This study aims to investigate the pharmacokinetics of bupivacaine liposomal injection (test preparation) in healthy subjects. The manufactured liposomal bupivacaine injection (EXPAREL®) was used as the reference formulation to evaluate the human bioequivalence between the two formulations.

Study Overview

• Status: Completed
• Conditions: Postoperative Local Analgesia
• Intervention / Treatment: Drug: Bupivacaine Liposome Injection T preparation; Drug: Bupivacaine Liposome Injection R preparation

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jilin
    • Changchun, Jilin, China, 130000
      • Jilin University First Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy male or female between the ages of 18 and 45 years, inclusive;
2. At least 50.0 kg for male subjects, 45.0 kg for female subjects, with a Body Mass Index (BMI) between 19.0-26.0 kg/m2, inclusive (BMI = weight/height2);
3. Subjects (including male subjects) agree to adopt effective physical contraceptive measurements and not plan pregnancy, or sperm/ovum donation during the study till 90 days after the last administration. Pregnancy tests of female subjects must be negative before and during the study and female subjects were not lactating. (see Section 14.2 for details);
4. Subjects who could understand the nature, significance, potential benefits, inconvenience, and potential risks of the study, understand the procedures and methods, be willing to complete the trial strictly following the protocol, and voluntarily sign the informed consent.

Exclusion Criteria:

1. Subjects with specific allergic diseases (asthma, urticaria, eczema, etc.) or allergic constitution (such as allergy to two or more drugs, food or pollen), or allergy to excipients and bupivacaine;
2. Subjects with history of serious diseases including but not limited to circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic disorders;
3. Abnormalities at the injection site (including skin diseases, open wounds, inflammation, scars, tattoos, etc.), which may affect the drug absorption;
4. Subjects who had undergone major trauma surgery within 6 months before the screening, or planned a surgery during the study;
5. Using any drugs that inhibit or induce the metabolism of drugs in liver within 30 days before the study (such as: inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors: SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones and antihistamines);
6. Use of any medication within 14 days prior to dosing (including vitamin products and herbal medicines);
7. Subjects who have taken any clinical investigational products or participated in the clinical research of medical devices within 3 months before the trial, or plan to participate in other clinical trials during the study;
8. Blood donation or massive loss (≥ 200 ml, excluding blood loss during menstrual period), received blood transfusion or blood products within 3 months before the trial;
9. Subjects who take more than 5 cigarettes per day on average within 3 months prior to the study or do not agree to prohibit smoking during the study;
10. Drinking frequently within 6 months before the trial, meaning 14 units of alcohol per week（1 unit = 360 mL beer or 45 mL of 40% spirits, or 150 mL wine), or disagree with the prohibition of alcohol during the study;
11. Subjects who were positive in drug abuse or had a history of drug abuse or use of illegal drugs within the past five years;
12. Clinical significance in vital signs, physical examination, ECG and clinical laboratory tests (chemistry, hematology, urinalysis, coagulation function);
13. Positive results in any one of Hepatitis B virus surface antigen, hepatitis C virus antibody, HIV antibody or syphilis serum reagin test;
14. Difficulty in venous blood collection or unable to tolerate venipuncture or abdominal subcutaneous injection;
15. Consumption of any special diet within 48 hours prior to dosing (including grapefruit, chocolate, xanthine rich food / beverage) and / or excessive consumption of tea, coffee, grapefruit juice, caffeinated beverage (more than 8 cups per day, 200 mL per cup) for the past three months;
16. Breath test for alcohol > 0.0 mg /mL;
17. Unable to complete the study due to personal reasons or other factors considered by the investigator as unsuitable to participate in the study (such as inability to understand the study requirements, poor compliance, etc.).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Bupivacaine liposome injection T preparation group	Drug: Bupivacaine Liposome Injection T preparation; Bupivacaine Liposome Injection T preparation; Drug: Bupivacaine Liposome Injection R preparation; Bupivacaine Liposome Injection R preparation; Other Names: EXPAREL®
Active Comparator: Bupivacaine liposome injection R preparation group	Drug: Bupivacaine Liposome Injection T preparation; Bupivacaine Liposome Injection T preparation; Drug: Bupivacaine Liposome Injection R preparation; Bupivacaine Liposome Injection R preparation; Other Names: EXPAREL®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum plasma concentration (Cmax).	Blood samples will be collected.	From 0 hour predose up to 240 hours postdose.
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t).	Blood samples will be collected.	From 0 hour predose up to 240 hours postdose.
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞).	Blood samples will be collected.	From 0 hour predose up to 240 hours postdose.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Observed time to reach Cmax (Tmax).	Blood samples will be collected.	From 0 hour predose up to 240 hours postdose.
Adverse events (AEs).		From 0 hour predose up to 35 days postdose.

Collaborators and Investigators

• Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): June 9, 2025
• Primary Completion (Actual): July 21, 2025
• Study Completion (Actual): July 21, 2025

Study Registration Dates

• First Submitted: December 1, 2025
• First Submitted That Met QC Criteria: December 10, 2025
• First Posted (Actual): December 12, 2025

Study Record Updates

• Last Update Posted (Actual): December 12, 2025
• Last Update Submitted That Met QC Criteria: December 10, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: HR-BBKY-BE-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No